HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 11/13/2012 -- Gilead Sciences (NASDAQ:GILD) shares pop on Monday, subsequent to the firm’s positive results from a mid-stage hepatitis C study. Gilead announced its interim data over the weekend from the ongoing Phase 2 ELECTRON evaluation that analyzed a 12-week course of therapy with the investigational nucleotide sofosbuvir, the NS5A inhibitor GS-5885 and ribavirin in patients with genotype 1 chronic hepatitis C virus (HCV) infection. These results will be presented on November 13 during the 63rd annual meeting of the American Association for the Study of Liver Diseases — The Liver Meeting 2012 — in Boston. Gilead Sciences, (NasdaqNM:GILD) is +8.918 - +13.72% from the previous close of $65.01. It traded between $71.58 - 74.34 with total traded volume of 30783976 shares. Keep a close eye on GILD, as the stock has been showing unusual moves over the past weeks. At Current market price, GILD has recovered +114.60% from its 52-week Low of 34.45 and has Pulled back +5.03% from its 52-week high of 70.39.
Should Investor Hold or Exit From GRPN: CHECK NOW FOR FREE
Crexus Investment (NYSE:CXS) is +1.33 - +11.98% from the previous close of $11.10. It traded between $12.32 - 12.67 with total traded volume of 20921368 shares. At Current Market Price, CXS is in distance of +10.59% from its 50-day Moving Average price of $11.24 and +21.20% from its 200-day Moving Average price of $10.2559. The law firm Finkelstein Thompson LLP announced that it is investigating potential claims on behalf of shareholders of CreXus Investment Corp, concerning the proposed acquisition of the Company by Annaly Capital Management Inc. Under the terms of the transaction, CreXus shareholders would receive $12.50 per share in cash. The total value of the transaction is approximately $839 million. The investigation is focused on the potential unfairness of the consideration to shareholders, the process by which the Company’s Board of Directors is considering the transaction, and potential conflicts of interest among CreXus’ Board members.
Are these stocks a buy or sell? Free Sign Up Here For Free Guide
Idenix Pharmaceut (NGM:IDIX) is very active today and traded between $4.22 - 4.72 with total traded volume of 4655178 shares. At a current price of 4.65, IDIX is +0.48 - +11.51% from the previous close of $4.17. Moreover, At Current Market Price, IDIX is in distance of +11.56% from its 50-day Moving Average price of $4.1682 and -37.56% from its 200-day Moving Average price of $7.4476. Idenix Pharmaceuticals, Inc.(IDIX) shares climbed 11.75% to $4.65. The company posted third quarter total revenues of $32.3 million, as compared to total revenues of $2.6 million in the third quarter of 2011. The Company reported a net income of $4.3 million, or $0.03 per basic and diluted share, for the third quarter ended September 30, 2012, compared to a net loss of $11.7 million, or $0.12 per basic and diluted share for the third quarter ended September 30, 2011. The company announced the presentation of safety and antiviral activity results for the Company`s clinical-stage hepatitis C virus (HCV) drug candidates - IDX719, a next-generation pan-genotypic NS5A inhibitor, and IDX184, a nucleotide polymerase inhibitor.
Should Investor Start Buying IDIX From Here For Long Term: Get A Free Report How to It Move From Here
Chimera Investmen (NYSE:CIM) is +0.22 - +8.63% from the previous close of $2.55. It traded between $2.61 - 2.78 with total traded volume of 37950644 shares. Keep a close eye on CIM, as the stock has been showing unusual moves over the past weeks. At Current market price, CIM has recovered +53.04% from its 52-week Low of 1.81 and has Pulled back -12.34% from its 52-week high of 3.16. The shares of the company gained 4% in the last one year.Chimera Investment Corp. (NYSE:CIM) is a specialty real estate investment trust which is managed by Fixed Income Discount Advisory Company (FIDAC), which in turn is a wholly owned subsidiary of Annaly Capital Management. The firm is an investor in residential mortgage-backed securities Rambus (NASDAQ:RMBS), commercial mortgage loans, residential mortgage loans, real estate-related securities, and currently pays an annual dividend of 36 cents on a yield of approximately 14.1 percent.
How Should Investors React to CIM Now? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to loose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)